183 related articles for article (PubMed ID: 21803707)
1. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
2. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
5. New therapy targets resistant non-small-cell lung cancers.
Jenks S
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
[No Abstract] [Full Text] [Related]
6. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
7. Update on HER1-3 in advanced non-small-cell lung cancer.
Horn L; Lovly C
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S369-71. PubMed ID: 23160321
[No Abstract] [Full Text] [Related]
8. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
9. The TAILOR study: to agree or to disagree?
Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
[No Abstract] [Full Text] [Related]
10. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
11. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.
Cheng L; Zhang S; Alexander R; Yao Y; MacLennan GT; Pan CX; Huang J; Wang M; Montironi R; Lopez-Beltran A
Future Oncol; 2011 Apr; 7(4):519-41. PubMed ID: 21463141
[TBL] [Abstract][Full Text] [Related]
12. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
14. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
15. Lung cancer in the era of targeted therapy: a cytologist's perspective.
Zakowski MF
Arch Pathol Lab Med; 2013 Dec; 137(12):1816-21. PubMed ID: 23597048
[TBL] [Abstract][Full Text] [Related]
16. For EGFR research, new targeted drugs mean new questions.
Vastag B
J Natl Cancer Inst; 2005 May; 97(9):628-30. PubMed ID: 15870431
[No Abstract] [Full Text] [Related]
17. Targeting resistance in lung cancer.
Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
[No Abstract] [Full Text] [Related]
18. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
19. New and emerging targeted treatments in advanced non-small-cell lung cancer.
Hirsch FR; Suda K; Wiens J; Bunn PA
Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
[TBL] [Abstract][Full Text] [Related]
20. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
